AUTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Autolus Therapeutics PLC (AUTL) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. The stock lacks strong proprietary trading signals, has mixed technical indicators, and its financial performance shows significant challenges. While analysts remain optimistic with high price targets, the company's financials and lack of recent positive news or catalysts make it prudent to hold off on investing for now.
The MACD histogram is positive at 0.046, indicating bullish momentum, but it is contracting. RSI is at 74.616, which is neutral. Moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 1.856), which may limit further upside in the short term.
Analysts have reiterated Buy ratings with optimistic price targets, citing the potential of the company's pipeline and expanding addressable markets. The company's product, Aucatzyl, has shown strong sales performance, and upcoming clinical updates in 2026 could act as a catalyst.
The company's financials are weak, with negative net income, declining EPS, and a gross margin of -35.15%. No recent news or significant insider/hedge fund activity has been reported. The stock has a 70% chance of a slight decline (-0.17%) in the next trading day. Additionally, there is no recent congress trading data or influential figure activity.
In Q3 2025, revenue remained flat at $21.19M YoY. Net income dropped by 3.63% YoY to -$79.12M, and EPS declined by 3.23% YoY to -0.3. Gross margin significantly worsened to -35.15%, indicating operational inefficiencies.
Analysts are optimistic, with H.C. Wainwright and Needham maintaining Buy ratings and price targets ranging from $8 to $11. Analysts highlight the potential of the company's pipeline and upcoming clinical updates but acknowledge skepticism around breakeven timelines.
